158 related articles for article (PubMed ID: 25997849)
1. Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China.
Huang XF; Wang KY; Liang ZH; Du RR; Zhou LN
Eur Neurol; 2015; 73(5-6):337-41. PubMed ID: 25997849
[TBL] [Abstract][Full Text] [Related]
2. Demographic and clinical features of patients with blepharospasm in southern Taiwan: a university hospital-based study.
Hwang WJ
Acta Neurol Taiwan; 2012 Sep; 21(3):108-14. PubMed ID: 23196730
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
4. Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections.
Yabumoto C; Osaki MH; Osaki T; Gameiro GR; Campos M; Osaki TH
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):475-478. PubMed ID: 36928309
[TBL] [Abstract][Full Text] [Related]
5. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
[TBL] [Abstract][Full Text] [Related]
7. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
9. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
Isshiki Y; Ishikawa H; Mimura O
Jpn J Ophthalmol; 2016 Nov; 60(6):486-491. PubMed ID: 27503401
[TBL] [Abstract][Full Text] [Related]
10. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
[TBL] [Abstract][Full Text] [Related]
11. Blepharospasm and apraxia of eyelid opening associated with anti-Hu paraneoplastic antibodies: a case report.
Choe CH; Gausas RE
Ophthalmology; 2012 Apr; 119(4):865-8. PubMed ID: 22264884
[TBL] [Abstract][Full Text] [Related]
12. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
Calace P; Cortese G; Piscopo R; Della Volpe G; Gagliardi V; Magli A; De Berardinis T
Eur J Ophthalmol; 2003 May; 13(4):331-6. PubMed ID: 12872788
[TBL] [Abstract][Full Text] [Related]
13. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm.
Johnstone SJ; Adler CH
Headache; 1998 May; 38(5):366-8. PubMed ID: 9630789
[TBL] [Abstract][Full Text] [Related]
14. Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm.
Tang M; Li W; Ji F; Li X; Zhang Y; Liu P
Psychol Health Med; 2019 Jun; 24(5):513-518. PubMed ID: 30463432
[TBL] [Abstract][Full Text] [Related]
15. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
[TBL] [Abstract][Full Text] [Related]
16. Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
Lee S; Park S; Lew H
Korean J Ophthalmol; 2018 Feb; 32(1):1-7. PubMed ID: 29376224
[TBL] [Abstract][Full Text] [Related]
17. Primary blepharospasm: diagnosis and management.
Defazio G; Livrea P
Drugs; 2004; 64(3):237-44. PubMed ID: 14871168
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.
Fang XB; Xie MS; Song ZB; Zhong ZG; Wang Y; Ou ZL; Dang C; Li L; Zhang WX
Neurol Sci; 2020 Mar; 41(3):645-652. PubMed ID: 31745757
[TBL] [Abstract][Full Text] [Related]
19. The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog.
Meyer-Lindenberg A; Wohlfarth KM; Switzer EN
Aust Vet J; 2003 Oct; 81(10):612-4. PubMed ID: 15080472
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin and blink rate in patients with blepharospasm and increased blinking.
Ferrazzano G; Conte A; Fabbrini G; Bologna M; Macerollo A; Defazio G; Hallett M; Berardelli A
J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):336-40. PubMed ID: 24963123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
